Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Cloudia Research S.p.A. is a specialized company focused on biotechnology research and development, particularly within the medical and healthcare sectors. Its primary purpose is to advance scientific knowledge and create innovative solutions for pressing medical challenges, targeting diseases that require novel therapeutic approaches. The company is known for leveraging cloud-based technologies to enhance data analysis and streamline collaborative research efforts, making it a leader in using digital tools to accelerate biotechnological advancements. As such, Cloudia Research impacts industries including pharmaceuticals, diagnostics, and medical device manufacturing. By integrating cutting-edge technology with biological research, the company plays a significant role in advancing personalized medicine and improving patient outcomes. With a commitment to scientific rigor and innovation, Cloudia Research S.p.A. contributes to the broader life sciences market, pushing the boundaries of what is possible in healthcare and treatment solutions.
€0.63
+€0.00 (+0.00%)
EOD Aug 14, 2026
Operating margin is thin at 8.90%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 21.0%, still solid. Margins contracted 6.3pp, which offsets some of the top-line progress.
ROIC dropped from 24.26% to 10.61%, capital efficiency is deteriorating. Negative free cash flow of -€2M. The business is consuming cash, not generating it.
4.4x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€7M
▲ +21.0% YoY
Net Income (TTM)
€562K
▼ -13.1% YoY
Op. Margin
8.90%
▼ -6.3pp YoY
ROIC
10.61%
▼ -13.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€2M
▲ +10.8% YoY
Op. Cash Flow (TTM)
€131K
▲ +79.7% YoY
Net Debt
€333K
Cash & Equiv.
€1M
3Y CAGR: +49.1%
Continue Research
At a P/E of 4.4, Cloudia Research S.p.A. (AGAIN.XMIL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cloudia Research S.p.A. scores 45/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Cloudia Research S.p.A. scores 45 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 8.9% operating margin and a 10.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AGAIN.XMIL's valuation and scores 45/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.